Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
IRIX's Cash to Debt is ranked higher than
93% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. IRIX: No Debt )
IRIX' s 10-Year Cash to Debt Range
Min: 0.59   Max: No Debt
Current: No Debt

Equity to Asset 0.77
IRIX's Equity to Asset is ranked higher than
80% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. IRIX: 0.77 )
IRIX' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.91
Current: 0.77

0.4
0.91
Interest Coverage 7.10
IRIX's Interest Coverage is ranked lower than
53% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. IRIX: 7.10 )
IRIX' s 10-Year Interest Coverage Range
Min: 6.53   Max: 9999.99
Current: 7.1

6.53
9999.99
F-Score: 6
Z-Score: 8.36
M-Score: -2.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.88
IRIX's Operating margin (%) is ranked higher than
73% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. IRIX: 6.88 )
IRIX' s 10-Year Operating margin (%) Range
Min: -43.43   Max: 15.91
Current: 6.88

-43.43
15.91
Net-margin (%) 5.83
IRIX's Net-margin (%) is ranked higher than
75% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. IRIX: 5.83 )
IRIX' s 10-Year Net-margin (%) Range
Min: -40.11   Max: 11.61
Current: 5.83

-40.11
11.61
ROE (%) 8.63
IRIX's ROE (%) is ranked higher than
78% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. IRIX: 8.63 )
IRIX' s 10-Year ROE (%) Range
Min: -118.41   Max: 21.28
Current: 8.63

-118.41
21.28
ROA (%) 6.62
IRIX's ROA (%) is ranked higher than
81% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. IRIX: 6.62 )
IRIX' s 10-Year ROA (%) Range
Min: -47.74   Max: 15.63
Current: 6.62

-47.74
15.63
ROC (Joel Greenblatt) (%) 22.49
IRIX's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. IRIX: 22.49 )
IRIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -180.64   Max: 41.18
Current: 22.49

-180.64
41.18
Revenue Growth (%) 5.90
IRIX's Revenue Growth (%) is ranked higher than
74% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. IRIX: 5.90 )
IRIX' s 10-Year Revenue Growth (%) Range
Min: -21.9   Max: 24.8
Current: 5.9

-21.9
24.8
EBITDA Growth (%) 10.50
IRIX's EBITDA Growth (%) is ranked higher than
86% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. IRIX: 10.50 )
IRIX' s 10-Year EBITDA Growth (%) Range
Min: -44.2   Max: 178.1
Current: 10.5

-44.2
178.1
EPS Growth (%) 11.20
IRIX's EPS Growth (%) is ranked higher than
82% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. IRIX: 11.20 )
IRIX' s 10-Year EPS Growth (%) Range
Min: -54.3   Max: 255.2
Current: 11.2

-54.3
255.2
» IRIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

IRIX Guru Trades in Q1 2013

Jim Simons 100,700 sh (+2.55%)
» More
Q2 2013

IRIX Guru Trades in Q2 2013

Jim Simons 107,000 sh (+6.26%)
» More
Q3 2013

IRIX Guru Trades in Q3 2013

Jim Simons 112,000 sh (+4.67%)
» More
Q4 2013

IRIX Guru Trades in Q4 2013

Jim Simons 161,100 sh (+43.84%)
» More
» Details

Insider Trades

Latest Guru Trades with IRIX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 40.80
IRIX's P/E(ttm) is ranked lower than
54% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. IRIX: 40.80 )
IRIX' s 10-Year P/E(ttm) Range
Min: 8.88   Max: 220.41
Current: 40.8

8.88
220.41
P/B 3.50
IRIX's P/B is ranked higher than
55% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. IRIX: 3.50 )
IRIX' s 10-Year P/B Range
Min: 0.41   Max: 4.06
Current: 3.5

0.41
4.06
P/S 2.30
IRIX's P/S is ranked higher than
60% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. IRIX: 2.30 )
IRIX' s 10-Year P/S Range
Min: 0.11   Max: 2.83
Current: 2.3

0.11
2.83
PFCF 223.70
IRIX's PFCF is ranked lower than
75% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. IRIX: 223.70 )
IRIX' s 10-Year PFCF Range
Min: 0.29   Max: 277.48
Current: 223.7

0.29
277.48
EV-to-EBIT 29.40
IRIX's EV-to-EBIT is ranked lower than
54% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. IRIX: 29.40 )
IRIX' s 10-Year EV-to-EBIT Range
Min: 12.9   Max: 2786.4
Current: 29.4

12.9
2786.4
Shiller P/E 143.00
IRIX's Shiller P/E is ranked lower than
71% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. IRIX: 143.00 )
IRIX' s 10-Year Shiller P/E Range
Min: 21   Max: 1080
Current: 143

21
1080

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.70
IRIX's Price/Net Cash is ranked higher than
50% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. IRIX: 15.70 )
IRIX' s 10-Year Price/Net Cash Range
Min: 2.69   Max: 31.17
Current: 15.7

2.69
31.17
Price/Net Current Asset Value 5.30
IRIX's Price/Net Current Asset Value is ranked higher than
75% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. IRIX: 5.30 )
IRIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 9.44
Current: 5.3

1.06
9.44
Price/Tangible Book 3.50
IRIX's Price/Tangible Book is ranked higher than
65% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. IRIX: 3.50 )
IRIX' s 10-Year Price/Tangible Book Range
Min: 0.66   Max: 3.99
Current: 3.5

0.66
3.99
Price/DCF (Projected) 3.20
IRIX's Price/DCF (Projected) is ranked lower than
62% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. IRIX: 3.20 )
IRIX' s 10-Year Price/DCF (Projected) Range
Min: 0.44   Max: 12.26
Current: 3.2

0.44
12.26
Price/Median PS Value 1.90
IRIX's Price/Median PS Value is ranked lower than
71% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. IRIX: 1.90 )
IRIX' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 2.95
Current: 1.9

0.13
2.95
Price/Graham Number 2.50
IRIX's Price/Graham Number is ranked higher than
59% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. IRIX: 2.50 )
IRIX' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 2.82
Current: 2.5

0.86
2.82
Earnings Yield (Greenblatt) 3.40
IRIX's Earnings Yield (Greenblatt) is ranked higher than
55% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. IRIX: 3.40 )
IRIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 7.8
Current: 3.4

0.1
7.8
Forward Rate of Return (Yacktman) 7.27
IRIX's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. IRIX: 7.27 )
IRIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -6.4   Max: 9.4
Current: 7.27

-6.4
9.4

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:IX4.Germany
Iridex Corporation was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, the company changed its name to IRIDEX Corporation and reincorporated in Delaware. It is a provider of therapeutic based laser systems and delivery devices used to treat eye diseases in ophthalmology and skin conditions in dermatology. Its ophthalmology products consist of laser systems, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases, including the three leading causes of irreversible blindness: diabetic retinopathy, glaucoma and age-related macular degeneration ("AMD"). In addition, its ophthalmology products are often used in vitrectomy procedures which are generally performed in the operating room and require a disposable single use laser probe to deliver the light to the back of the eye. Its laser systems consist of IQ products which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems; and its OcuLight products including OcuLight TX, OcuLight Symphony (Laser Delivery System), OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. The Company utilizes a systems approach to product design. Each system includes a console, which generates the laser energy, and a number of interchangeable peripheral delivery devices for use in specific clinical applications. Customers include research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics (outpatient). The Company sells and markets its products in the United States predominantly through its direct sales force and internationally through approximately 70 independent distributors into over 100 countries. The Company has issued 26 United States patents and 17 foreign patents. It is subject to extensive regulation by numerous governmental authorities, including federal, state, and foreign governmental agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide